The hiring comes after the company submitted a filing with the Securities and Exchange Commission in January to go public.

Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative ...

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

Corneal graft survival rates are similar between those who later receive trabeculectomy, cyclophotocoagulation, or drainage devices implants.

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

We present a case of unilateral, secondary open-angle glaucoma due to an underlying diffuse iris melanoma. The patient was referred by his ophthalmologist with uncontrolled, elevated intraocular ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

Leerink Partners analyst Marc Goodman has maintained their bullish stance on OPT stock, giving a Buy rating yesterday.Invest with Confidence: ...

In this Healio Video Perspective from Hawaiian Eye 2025, Greg Kunst, CEO of Aurion Biotech, discusses positive phase 1/2 data for the company’s cell therapy for corneal endothelial disease.

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...